Study of LTZ-232 for advanced colorectal and other solid tumors
Part of Cancer, Digestive system clinical trials.
This study tests an experimental drug called LTZ-232 in people with advanced colorectal cancer or other solid tumors that have not responded to standard treatments. The goal is to see if it is safe and if it can shrink or slow the growth of tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic colorectal cancer (cancer that has spread) that has not improved with standard treatments.
- Your tumors can be measured on scans (like CT or MRI).
- You are able to take care of yourself (able to do daily activities without help).
- Your blood tests show your liver, kidneys, and other organs are working well.
- You do not have active hepatitis B or C, uncontrolled brain metastases, or active autoimmune disease.
- You have not previously been treated with a drug that targets a protein called EpCAM (like LTZ-232).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests LYL273, a new targeted treatment, for people with metastatic colorectal (colon) cancer that has returned or not responded to standard chemo. It’s designed to see how well the drug can control the cancer and what side effects it causes.
This study tests a new imaging agent (a special dye) that might help doctors see tumors more clearly in people with certain advanced cancers. You would receive the dye and then have scans to see if it highlights cancer areas.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study tests an experimental drug called CT3001 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective, and for some patients with colorectal cancer, it may be combined with standard chemotherapy.
This trial tests an experimental drug called LM-350 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called LM-168, either alone or combined with another cancer treatment, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it can shrink tumors or slow their growth.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.